Neda Heidari, MD
Behavioral Neurology & Neuropsychiatry · Oxnard, CANPI 1003028556
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 524 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 43 manufacturers reported payments, led by AbbVie at 38.1% of the total. 2025 is the largest year on record at $2,594, 3.3 times the $789 reported in 2019.
Across 524 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Pfizer$886
- Biogen$665
- Acadia Pharmaceuticals Inc$401
- UCB, Inc.$391
- Novartis$279
- plus $3K from 37 others
What the payments were for
- Speaking & faculty fees$160%
- Food & beverage$8,37099%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few behavioral neurology & neuropsychiatry providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 67 | $741,721 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 62 | $694,491 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 33 | $462,590 |
| NuplazidPimavanserin Tartrate | 22 | $204,778 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 14 | $194,604 |
| IngrezzaValbenazine Tosylate | 14 | $118,449 |
| AustedoDeutetrabenazine | 11 | $71,447 |
| UbrelvyUbrogepant | 54 | $59,655 |
| BotoxOnabotulinumtoxina | 38 | $57,149 |
| Nurtec OdtRimegepant Sulfate | 31 | $55,825 |
| Aimovig AutoinjectorErenumab-Aooe | 66 | $55,294 |
| QuliptaAtogepant | 36 | $33,703 |
| OzempicSemaglutide | 12 | $22,815 |
| MounjaroTirzepatide | 20 | $20,462 |
| Rivastigmine | 67 | $17,597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $19 | $741,72167 claims |
| CSL BehringPrivigen | $71 | $694,49162 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $161 | $462,59033 claims |
| Acadia Pharmaceuticals IncNuplazid | $401 | $204,77822 claims |
| AbbVieUbrelvy, Botox, Qulipta | $3,213 | $150,507128 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $11 | $118,44914 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $44 | $71,44711 claims |
| PfizerNurtec Odt | $886 | $55,82531 claims |
| Lilly USA, LLCMounjaro | $159 | $20,46220 claims |
| Neurelis, Inc.Valtoco | $189 | $13,51211 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $30 | $3,88021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Californiaon file to place this against a meaningful peer group, so we don't.
Other behavioral neurology & neuropsychiatry in Oxnard
- Collins LiuSan Diego$37K
- Seyed SajjadiOrange$10K
- Sharon ShaStanford$8K
- Michael FrazierWestminster$8K
- Gabriel LegerSan Diego$4K
- Paramjit SinghChico$4K
- Peter WagnerRancho Mirage$666
- Balasubramaniam GulasekaramCerritos$310
- Anish DhamijaSan Diego$57
- Oluseyi AwodeleCarlsbad$46
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.